Attachment of a ³²P-phosphate to the 3′ Terminus of a DNA Oligonucleotide

Materials and Reagents

1. Illustra MicroSpin G-25 columns (Cytiva, catalog number: 27532501 ), stored at room temperature
2. 3′-modified DNA oligonucleotide (Integrated DNA Technologies) (see Procedure for details), stored at -20 °C
3. Phosphate shuttle RNA oligonucleotide (in vitro transcribed or commercially synthesized, Integrated DNA Technologies), stored at -80 °C
4. Splint RNA oligonucleotide (in vitro transcribed or commercially synthesized, Integrated DNA Technologies), stored at -80 °C
5. T4 polynucleotide kinase, 10,000 U/ml (New England Biolabs, catalog number: M0201S ), stored at -20 °C
6. T4 polynucleotide kinase reaction buffer, 10x (New England Biolabs, catalog number: B0201S ; included with product M0201), stored at -20 °C
7. [γ-³²P]-ATP EasyTide, 3000 Ci/mmol, 10 mCi/ml, 1 mCi (PerkinElmer, catalog number: BLU502A001MC ), stored at -20 °C
8. T4 RNA ligase 2, 10,000 U/ml (New England Biolabs, catalog number: M0239S ), stored at -20 °C
9. T4 RNA ligase 2 reaction buffer, 10x (New England Biolabs; included with product M0239S ), stored at -20 °C
10. Common reagents:
    NaOH (1.35 M stock)
    HCl (1.35 M stock)
    KCl
    Tris-Cl
    EDTA
    Sodium citrate
    MilliQ water (all instances of the word “water” in this protocol refer to MilliQ water)
11. 5x annealing buffer (see Recipes), stored at 4 °C
12. 1x RNA storage buffer (see Recipes), stored at 4 °C
    

Equipment

1. Standard shielding and other protective equipment for work with ³²P
2. Temperature-controlled block and/or thermocycler
3. Vortexer and microcentrifuge (for use with MicroSpin G-25 columns)
4. Optional: benchtop radiation counter (Bioscan QC-4000)
   

Procedure

1. Order the DNA oligonucleotide with the appropriate modifications
   1. Order your DNA oligonucleotide with sequence of interest (Note 1). The 3′-most nucleotide should be modified to be a ribonucleotide. The penultimate nucleotide (immediately 5′ to the ribonucleotide) should be modified to be a 2′-O-methylribonucleotide. To specify these modifications in the IDT ordering interface, begin with an order for an RNA oligonucleotide at 100 nmol scale. If the sequence of your DNA oligonucleotide is NNNNNN-3′, your sequence input should be NNNNmNrN.
      In the example presented in this protocol, the DNA oligonucleotide sequence is:
      5′-GTCATAATGATTTTATCTTCTGGATTGTTGTAAGCAGCATTTGAGCAAAAATCTGTTmGrC-3′, where all letters indicate deoxynucleotides except “mG” (which indicates 2′-O-methylguanosine) and “rC” (which indicates cytidine).
   2. Resuspend the DNA oligonucleotide to 10 µM in water (Note 2).
      
      
      
2. Order or transcribe the phosphate shuttle RNA oligonucleotide and the splint RNA oligonucleotide
   1. The phosphate shuttle RNA oligonucleotide can be ordered from an oligonucleotide synthesis company or produced by in vitro transcription. If producing by in vitro transcription (Notes 3 and 4), use a method whose final product contains a 5′-OH (either by treating a T7 RNA polymerase product with phosphatase or including a self-cleaving hammerhead ribozyme in the transcript). It is essential that the phosphate shuttle RNA contain a 5′-OH for the 5′-radiolabeling step.
      1. Phosphate shuttle RNA oligonucleotide sequence (Note 5):
         5′-GGGUCGGCAUGGCAUCUC-3′
      2. We include below the sequence of an in vitro transcription DNA template for T7 RNA polymerase to generate the phosphate shuttle RNA oligonucleotide (Note 6). Transcripts from this template contain a 5′ hammerhead ribozyme that cleaves to yield a 5′-OH on the final phosphate shuttle oligonucleotide.
         5′-GTCGAAATTAATACGACTCACTATAGGCGACCCCTGATGAGGCCTTCGGGCCGAAACGGTGAAAGCCGTAGGGTCGGCATGGCATCTC-3′
   2. The 5′ half of the splint RNA oligonucleotide should be complementary to the phosphate shuttle RNA oligonucleotide. The 3′ half of the splint RNA oligonucleotide should be complementary to the 3′ end of the DNA oligonucleotide to be labeled. The splint RNA oligonucleotide can be ordered from an oligonucleotide synthesis company or produced by in vitro transcription. The substituents on either end of this oligonucleotide are unimportant, as the ligase enzyme will bind to its center.
      1. Sequence of splint RNA oligonucleotide in this example:
         5′-GGAGAUGCCAUGCCGACCCGCAACAGAUUUUUGCUCA-3′
      2. We include below the sequence of an in vitro transcription DNA template for T7 RNA polymerase to generate the splint RNA oligonucleotide:
         5′-GTCGAAATTAATACGACTCACTATAGGAGATGCCATGCCGACCCGCAACAGATTTTTGCTCA-3′
   3. Resuspend each RNA oligonucleotide to 10 µM in RNA storage buffer.
      
      
      
3. 5′-radiolabel the phosphate shuttle RNA oligonucleotide
   1. Combine the following reagents (50 µl total reaction volume) (Note 7):
      5 µl 10x T4 PNK buffer
      30 µl water
      5 µl phosphate shuttle RNA oligonucleotide (10 µM stock)
      2.5 µl T4 PNK enzyme (10,000 U/ml stock)
      7.5 µl [γ-³²P]-ATP (3000 Ci/mmol, 10 mCi/ml stock)
   2. Allow phosphorylation to progress at 37 °C for 2 h.
   3. Heat-inactivate the T4 PNK by incubating at 65 °C for 20 min.
   4. Add 50 µl water to the reaction.
   5. If interested in determining yield, use the benchtop radiation counter to measure the radioactivity in the reaction at this step.
   6. Spin the reaction through a MicroSpin G-25 column (no resin pre-equilibration necessary), following the manufacturer’s instructions. This step largely removes any free [γ-³²P]-ATP that may remain after the reaction.
   7. Assuming complete recovery of the RNA oligonucleotide, you should have 100 µl of eluate containing 500 nM RNA oligonucleotide, some fraction of which has a 5′-³²P-phosphate. Use the benchtop radiation counter to measure the radioactivity in the eluate, and determine the efficiency of 5′-radiolabeling by comparing to the radioactivity measurement recorded before free ATP removal.
      
      
4. Anneal ligase substrates
   1. For each DNA oligonucleotide to be 3′-radiolabeled, combine the following (33 µl total reaction volume):
      6.6 µl 5x annealing buffer
      0.3 µl water
      24 µl 5′-radiolabeled phosphate shuttle RNA oligonucleotide (500 nM stock, directly from eluate in previous step)
      1 µl modified DNA oligonucleotide (10 µM stock)
      1.1 µl splint RNA oligonucleotide (10 µM stock)
   2. Place the annealing reaction on a thermocycler, and run the following temperature program (Note 8):
      1. 95 °C, 2 min.
      2. Cool to 25 °C over the course of 40 min.
      3. Hold at 25 °C.
      
      
5. Ligate the DNA oligonucleotide to the phosphate shuttle RNA oligonucleotid
   1. To the 33-µl annealing reaction, add:
      4 µl 10x T4 RNA ligase 2 reaction buffer
      1 µl 40 mM MgCl₂
      2 µl T4 RNA ligase 2 (10,000 U/ml stock)
   2. Incubate at 37 °C overnight (~16 h). If performing quality control, keep a sample from immediately after this incubation to run on a gel and determine ligation efficiency (Figure 3).
      
      
      Figure 3. Example autoradiograph of denaturing PAGE analysis. Lane 1: products of ligation reaction, standard protocol. Lane 2: products of ligation reaction using a DNA oligonucleotide that omits the 2′-O-methyl modification at the penultimate position (but retains the ribonucleotide modification at the final position), demonstrating the importance of the 2′-O-methyl modification for ligation efficiency. Lanes 3-7: products after RNA degradation of the ligation products in lane 1 with [NaOH] at 20 mM (lane 3), 50 mM (lane 4), 100 mM (lane 5), 150 mM (lane 6), and 200 mM (lane 7). The band in lane 6 represents the product generated by the conditions recommended in this protocol.
      
      
      
6. Degrade RNA
   1. To the 40-µl ligation reaction, add 5 µl 1.35 M NaOH. Mix thoroughly.
   2. Incubate at 95 °C for 10 min.
   3. Place on ice, and immediately add 5 µl 1.35 M HCl. Mix thoroughly.
      
      
      
7. Remove salts and mononucleotides by buffer exchange
   1. Pre-equilibrate a MicroSpin G-25 column with 20 mM Tris-Cl, pH 7.9 (room temperature) according to the manufacturer’s instructions (5 x 400-µl equilibration spins).
   2. Apply the 50-µl degradation reaction to the column, and spin according to the manufacturer’s instructions. Add 50 µl water to the eluate.
   3. At this point, the sample should have 100 µl total volume, containing 10 mM Tris-Cl, pH 7.9 and 100 nM 3′-radiolabeled DNA oligonucleotide (as well as the heat-inactivated kinase and ligase enzymes).
      
      
      
8. Yield and quality check
   1. Use the benchtop radiation counter to check the yield of transfer of radioactivity from the phosphate shuttle RNA oligonucleotide to the final DNA oligonucleotide. We commonly see recovery of ~75% of transferable phosphates (Note 9).
   2. Run a sample of the labeled DNA oligonucleotide on denaturing PAGE to verify that the sample contains a pure radiolabeled DNA fragment of the correct size (Notes 10 and 11, Figure 3).
   3. Store the radiolabeled DNA at -20 °C. The limiting factor for the expiration of the radiolabeled oligonucleotide is the radioactivity, as the chemical stability of the product (> years) long outlasts the radioactive decay lifetime of ³²P (half-life 14 days). The product can continue to be used as long as it retains enough radioactivity for the researcher’s particular experimental purposes.

Notes

1. For the purposes of mapping a DNA cleavage site with single-nucleotide resolution, the baseline purification option from oligonucleotide synthesis companies is often insufficient (the product contains significant concentrations of truncated synthesis products that may confound experimentally important cleavage products). To achieve adequate DNA oligonucleotide purity before 3′-radiolabeling, either perform a PAGE-purification in house or opt for more extensive purification in your commercial order.
2. Standard precautions for working with RNA should be followed. Keep gloves and surfaces clean, and when possible, use filter-containing pipette tips. We do not detect any RNase activity when using MilliQ water in reactions containing RNA, but the experimentalist can purchase commercially certified RNase-free water if there are suspicions of RNase contamination. RNA samples should be stored at -80 °C (ideal) or -20 °C when not in use, but they can be briefly handled on a room-temperature bench between the steps described in this protocol.
3. Consult any standard protocol for the optional steps involving in vitro transcription, PAGE purification, analytical PAGE, and autoradiography.
4. If RNA oligonucleotides are produced by in vitro transcription, the resulting transcript should then be PAGE-purified for optimal results.
5. The phosphate shuttle RNA oligonucleotide sequence is arbitrary, and we simply included here a sequence that worked well in our experiments. This sequence could presumably be changed provided that compensatory substitutions are also made in the splint RNA oligonucleotide.
6. For the in vitro transcription template sequences included in this protocol, only the top strand is shown. Double-stranded DNA templates were assembled and amplified by polymerase chain reaction.
7. This protocol yields enough 5′-radiolabeled phosphate shuttle RNA oligonucleotide to 3′-radiolabel 4 different DNA oligonucleotides (with a final yield of 100 µl at 100 nM for each 3′-radiolabeled DNA oligonucleotide). Scale the volumes up or down to suit the needs of your particular application, taking care to spread the sample across multiple G-25 MicroSpin columns if the volume limitation of an individual column is exceeded.
8. In the absence of a thermocycler, an alternative annealing procedure is as follows: incubate samples at 95 °C for 2 min on a heat block, turn off the heat block, and allow the system to gradually equilibrate to room temperature.
9. The ~75% yield is after accounting for the stoichiometric excess of phosphate shuttle RNA oligonucleotide in the annealing reaction, which results in a 17% subpopulation whose 5′-³²P-phosphate is unavailable for transfer. The absolute fraction of recovered radioactivity is ~60%.
10. The most common contaminants are depurination products and n+1 products (some fraction of the DNA molecules contain two ribonucleotides on the 3′ end instead of one, as the n+1 phosphodiester was not cleaved in the RNA degradation reaction). In our preparations, these products were minor or not detected at all (there was variation between different probe preparations), and they did not interfere with our experiments. If the contaminant concentration is too high for your particular oligonucleotide preparation, try quenching the RNA degradation reaction with HCl at a variety of temperatures or time points. Identify a combination of temperature and quenching time that yields an acceptable balance of depurination products (which accumulate over time) and n+1 products (which disappear over time due to cleavage and release of the terminal ribonucleotide). Alternatively, PAGE-purify the 3′-radiolabeled DNA oligonucleotide for maximal purity.
11. The identity of the final species can also be confirmed by treating with T4 PNK and checking by PAGE/autoradiography that all radioactivity has moved from the DNA oligonucleotide to an inorganic phosphate (due to the phosphatase activity of the T4 PNK enzyme that removes 2′,3′-cyclic phosphates).
    

Recipes

1. 5x annealing buffer
   50 mM Tris-Cl, pH 7.9 at 25 °C
   250 mM KCl
   5 mM EDTA
2. 1x RNA storage buffer
   2 mM sodium citrate, pH 6.4 at 25 °C
   0.1 mM EDTA, pH 8.0
   

Acknowledgments

This protocol was developed with support from a National Science Foundation Graduate Research Fellowship (J.C.C.) and National Science Foundation Award # MCB-1817593 (J.A.D.). The protocol was originally developed for use in Cofsky et al., 2020. We thank David Colognori for a critical reading of the protocol draft.

Competing interests

The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Felix Biosciences, and Inari. J.A.D. is a Director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche. J.C.C. has no competing interests to report.

Ethics

This protocol does not include the use of human or animal subjects.

References

1. Cofsky, J. C., Karandur, D., Huang, C. J., Witte, I. P., Kuriyan, J. and Doudna, J. A. (2020). CRISPR-Cas12a exploits R-loop asymmetry to form double-strand breaks. Elife 9: e55143.
2. Jay, E., Bambara, R., Padmanabhan, R. and Wu, R. (1974). DNA sequence analysis: a general, simple and rapid method for sequencing large oligodeoxyribonucleotide fragments by mapping. Nucleic Acids Res 1(3): 331-353.
3. Nandakumar, J. and Shuman, S. (2004). How an RNA ligase discriminates RNA versus DNA damage. Mol Cell 16(2): 211-221.
4. Wu, R., Jay, E., and Roychoudhury, R. (1976). Nucleotide Sequence Analysis of DNA. In: Methods in Cancer Research. Vol. 12. Busch, H. (Ed.). Academic Press, 87-176.